B
Beow Y. Yeap
Researcher at Harvard University
Publications - 282
Citations - 23610
Beow Y. Yeap is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 80, co-authored 261 publications receiving 20562 citations. Previous affiliations of Beow Y. Yeap include University of Rochester & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw,Beow Y. Yeap,Mari Mino-Kenudson,Subba R. Digumarthy,Daniel B. Costa,Rebecca S. Heist,Benjamin Solomon,Hannah Stubbs,Sonal Admane,Ultan McDermott,Jeffrey Settleman,Susumu Kobayashi,Eugene J. Mark,Scott J. Rodig,Lucian R. Chirieac,Eunice L. Kwak,Thomas J. Lynch,A. John Iafrate +17 more
TL;DR: EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics and patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.
Journal ArticleDOI
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke,Kreshnik Zejnullahu,Yi-Long Wu,Youngchul Song,Dora Dias-Santagata,Eugene Lifshits,Luca Toschi,Andrew H. Rogers,Tony Mok,Lecia V. Sequist,Neal I. Lindeman,Carly Murphy,Sara Akhavanfard,Beow Y. Yeap,Yun Xiao,Yun Xiao,Marzia Capelletti,A. John Iafrate,Charles Lee,James G. Christensen,Jeffrey A. Engelman,Pasi A. Jänne +21 more
TL;DR: Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy is highlighted.
Journal ArticleDOI
EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor,Alice T. Shaw,Lecia V. Sequist,Xiujun Fu,Christopher G. Azzoli,Zofia Piotrowska,Tiffany Huynh,Ling Zhao,Linnea Fulton,Katherine Schultz,Emily Howe,Anna F. Farago,Ryan J. Sullivan,James R. Stone,Subba R. Digumarthy,Teresa Moran,Aaron N. Hata,Yukako Yagi,Beow Y. Yeap,Jeffrey A. Engelman,Mari Mino-Kenudson +20 more
TL;DR: In this paper, the authors evaluated response patterns among EGFR-mutant, ALK-positive, and EGFR wild-type/ALK-negative patients and identified 58 patients treated with PD-1/PD-L1 inhibitors.
Journal ArticleDOI
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Alice T. Shaw,Beow Y. Yeap,Benjamin Solomon,Gregory J. Riely,Justin F. Gainor,Jeffrey A. Engelman,Geoffrey I. Shapiro,Daniel B. Costa,Sai-Hong Ignatius Ou,Mohit Butaney,Ravi Salgia,Robert G. Maki,Marileila Varella-Garcia,Robert C. Doebele,Yung-Jue Bang,Kimary Kulig,Paulina Selaru,Yiyun Tang,Keith D. Wilner,Eunice L. Kwak,Jeffrey W. Clark,A. John Iafrate,D. Ross Camidge +22 more
TL;DR: In patients with advanced, ALK-positive NSCLC, crizotinib therapy is associated with improved survival compared with that of crizotib-naive controls, and ALK rearrangement is not a favourable prognostic factor in advanced NSClC.
Journal ArticleDOI
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Scott J. Rodig,Mari Mino-Kenudson,Sanja Dacic,Beow Y. Yeap,Alice T. Shaw,Justine A. Barletta,Hannah Stubbs,Kenneth Law,Neal I. Lindeman,Eugene J. Mark,Pasi A. Jänne,Thomas J. Lynch,Bruce E. Johnson,A. John Iafrate,Lucian R. Chirieac +14 more
TL;DR: Lung adenocarcinomas with ALK rearrangements are uncommon in the western population and represent a distinct entity of carcinomas with unique characteristics, and dual diagnostic testing, with FISH and immunohistochemistry, should be considered.